CT-P13: design, development, and place in therapy

CT-P13: design, development, and place in therapy

Tommaso Gabbani,1 Simona Deiana,2 Vito Annese3 1Gastroenterology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, 2Division of Gastroenterology, AOU Careggi University Hospital, Florence, Italy; 3Gastroenterology Department, Valiant Clinic, Dubai, UAE Abstract: The introduction...

Full description

Bibliographic Details
Main Authors:	Gabbani T, Deiana S, Annese V
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-06-01
Series:	Drug Design, Development and Therapy
Subjects:	CT-P13 Infliximab biosimilar biologic therapy Crohn disease Ulcerative Colitis
Online Access:	https://www.dovepress.com/ct-p13-design-development-and-place-in-therapy-peer-reviewed-article-DDDT

Similar Items

Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
by: Ana Valido, et al.
Published: (2019-10-01)

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)
by: Kim S, et al.
Published: (2020-07-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
by: Tomoo Nakagawa, et al.
Published: (2019-10-01)

Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation
by: O V Knyazev, et al.
Published: (2019-08-01)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
by: Jang Wook Lee, et al.
Published: (2016-04-01)

Safety profile of anti-tumor necrosis factor therapy in inflammatory bowel disease – a single center experience
by: Piotr Eder, et al.
Published: (2015-09-01)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
by: Sang Hyoung Park, et al.
Published: (2020-01-01)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
by: Corrado Campochiaro, et al.
Published: (2021-09-01)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria
by: F. Bermejo, et al.
Published: (2004-02-01)

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease Posición conjunta de la Sociedad Española de Patología Digestiva y de la Sociedad Española de Farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal
by: Federico Argüelles-Arias, et al.
Published: (2013-01-01)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
by: Viscido A, et al.
Published: (2019-04-01)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
by: Sara Salvador-Martín, et al.
Published: (2021-01-01)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
by: Sara Salvador-Martín, et al.
Published: (2020-05-01)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
by: Choon Jin Ooi, et al.
Published: (2019-07-01)

Is safety infliximab during pregnancy in patients with inflammatory bowel disease? ¿El tratamiento con infliximab es seguro durante el embarazo en pacientes con enfermedad inflamatoria intestinal?
by: Federico Argüelles-Arias, et al.
Published: (2012-02-01)

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients
by: Alejandro Pérez-Pitarch, et al.
Published: (2015-03-01)

Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Peyman Adibi, et al.
Published: (2011-01-01)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
by: Manuel Sutter, et al.
Published: (2021-08-01)

External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab
by: Celine Konecki, et al.
Published: (2021-08-01)

Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease
by: Ryan Morrow, et al.
Published: (2021-05-01)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
by: Abdalla A, et al.
Published: (2017-03-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
by: A. López San Román, et al.
Published: (2004-06-01)

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01)

Targeted therapy of inflammatory bowel diseases: realities and prospects
by: I. V. Maev, et al.
Published: (2018-04-01)

Inflammatory Bowel Diseases: Focus on Therapy
by: Cristina Tocia, et al.
Published: (2018-02-01)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
by: Shin Ju Oh, et al.
Published: (2021-07-01)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
by: Hyun Il Seo, et al.
Published: (2014-07-01)

Platelet indices as potential biomarkers for determining active ulcerative colitis and assessing the efficacy of biological treatment – experience of a single centre – a pilot study
by: Michalak Agata, et al.
Published: (2019-12-01)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
by: Magdalena Kaniewska, et al.
Published: (2020-11-01)

Blir behandlingen av reumatoid artrit mer effektiv med tillägg av infliximab och är biosimilaren CT-P13 lika effektiv?
by: Brkic, Linda
Published: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
by: Helena Rolandsdotter, et al.
Published: (2017-03-01)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
by: Yazici Y, et al.
Published: (2018-10-01)

INFLIXIMAB IN THE TREATMENT OF SEVERE STEROID-REFRACTORY ULCERATIVE COLITIS – A CASE REPORT
by: Darja Urlep, et al.
Published: (2004-04-01)

Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
by: Soo-Kyung Park, et al.
Published: (2019-12-01)

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
by: Bernard Combe, et al.
Published: (2021-04-01)